Anatomic Abstracts |
January 2002
Immunohistochemistry as a predictor of long-term survival in PMM Bongiovanni M, Cassoni P, De Giuli P, et al. p27kip1 immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer. 2001;92:1245-1250. Reprints: Dr. Gianni Bussolati, Dept. of Oncology, University of Turin, Via Santena 7, 1-10126 Torino, Italy; bussolati@monlinette.unito.it Role of histologic grade in managing cancers of the head and neckThe authors evaluated the role of histologic grade (World Health Organization criteria) as an independent predictor of distant metastases for carcinomas of the head and neck. They studied 1,266 consecutive patients treated with definitive or postoperative radiotherapy between 1989 and 1997. All patients received at least 50 Gy, and all stages and subsites of head and neck cancers were included. The authors found a strong correlation between grade and N stage (P<.000001). The metastases-free survival was 98 percent, 90 percent, and 72 percent for grades one, two, and three, respectively (P<.000001). For stage N0 patients, metastases-free survival was greater than 90 percent, regardless of grade. For N1 patients, it was greater than 90 percent for grades one and two tumors but dropped to 75 percent for grade three tumors (P=.001). For patients with N2 and N3 disease, metastases-free survival was 91 percent, 79 percent, and 59 percent for grades one, two, and three, respectively (P=.008). Similar findings were noted when only neck control was analyzed. The authors concluded that patients with grades one and two tumors are at low risk for distant metastases, except for those within N3 disease. Patients with grade two and N3 disease and those with grade three disease with any lymph node metastases have a high rate of distant metastases and should be considered for systemic treatment. Fortin A, Couture C, Doucet R, et al. Does histologic grade have a role in the management of head and neck cancers? J Clin Oncol. 2001;19:4107-4116. Reprints: Dr. André Fortin, Dept. of Radiation-Oncology de l’université Laval, L’Hôtel-Dieu de Québec, 11 Cte du Palais, Québec, Canada GIR 2J6; afortin@videotron.ca Arrhythmogenic right ventricular cardiomyopathyThe authors of an Italian study subclassified the patterns of fatty infiltration observed in 27 patients (12 autopsies, 15 heart transplants) with arrhythmogenic right ventricular cardiomyopathy who were seen at two referral university hospitals. They divided the patients into two groups: infiltrative with a lace-like pattern of transmural fatty infiltration and strands of normal residual cardiomyocytes (n=11), and cardiomyopathic with massive replacement by fibro-fatty tissue and cardiomyopathic changes such as hypertrophy and myofibril loss of residual cardiomyocytes (n=16). Hearts from the infiltrative group primarily were obtained at autopsy from patients who died suddenly. In this group, fatty substitution was limited almost exclusively to the right ventricle, and mitral valve dysplasia was often present. Hearts from the cardiomyopathic group were primarily from heart transplant patients with congestive heart failure. Fibro-fatty replacement was more extensive because it was usually biventricular. Despite these differences in clinical outcome and morphologic features, the patients in the two groups were similar with regard to age, sex distribution, occurrence of life-threatening ventricular arrhythmias, and prevalence of family history of sudden death, arrhythmias, and cardiomyopathy. The authors claim that the infiltrative and cardiomyopathic patterns present different clinical and pathological subsets of arrhythmogenic right ventricular cardiomyopathy. They say that differentiating between the two patterns on endomyocardial biopsy is feasible and could provide important prognostic information. D’Amati G, Leone O, Di Gioia C, et al. Arrhythmogenic right ventricular cardiomyopathy: clinicopathologic correlation based on a revised definition of pathologic patterns. Hum Pathol. 2001;32:1078-1086. Reprints: Dr. Pietro Gallo, Dipartimento di Medicina Sperimental e Patologia, Sezione di Anatomia Pathologica, Policlinico Umberto I, Viale Reginal Elena 324, 00161 Roma, Italy An immunohistochemical marker of prostate carcinoma Jiang Z, Woda BA, Rock KL, et al. P504S. A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404. Reprints: Dr. Zhong Jiang, Dept. of Pathology, University of Massachusetts Medical School, 55 Lake Ave., Worcester, MA 01655; jiangz@ummhc.org Classifying pN0 and pNX Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pN0. Cancer. 2001;92:452 Reprints: Dr. Leslie H. Sobin, GI Pathology, Armed Forces Institute of Pathology, 14th St. and Alaska Ave., Washington, DC 20306; sobin@afip.osd.miln |
|||
|